Clinical trialNCT02960594CompletedPhase 1Interventional

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

SponsorInovio PharmaceuticalsEnrollment93Breast CancerColoRectal CancerEsophageal CancerGastric CancerHead and Neck CancerHepatoCellular Carcinoma+3 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subjects will be enrolled into one of ten treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Anthony Shields, MD
Karmanos Cancer Center (Wayne State University)
Principal Investigator
clinicaltrials.gov ↗
Ashish Chintakuntlawar, MBBS, PhD
Mayo Clinic, Rochester, MN
Principal Investigator
clinicaltrials.gov ↗
Autumn McRee, MD
University of North Carolina
Principal Investigator
clinicaltrials.gov ↗
Jennifer Johnson, MD
Thomas Jefferson University Hospitial
Principal Investigator
clinicaltrials.gov ↗
Nathan Bahary, MD
University of Pittsburgh
Principal Investigator
clinicaltrials.gov ↗
Robert Vonderheide, MD, PhD
University of Pennsylvania
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

INO-1400INO-1401INO-9012

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2014
Primary completion: 9 Nov 2018
Completion: 9 Nov 2018
Last update posted: 19 Nov 2018
Registered enrollment: 93
Registry id: NCT02960594

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.